Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis

@article{Chabi2015RandomizedCT,
  title={Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis},
  author={Almira Chabi and Ying Zhang and Saheeda Jackson and Roger K. Cady and Christopher R. Lines and W. Joseph Herring and Kathryn M. Connor and David Michelson},
  journal={Cephalalgia},
  year={2015},
  volume={35},
  pages={379 - 388}
}
Background This study explored whether antagonism of orexin receptors might be an effective mechanism for migraine prevention. Methods We conducted a randomized, double-blind, placebo-controlled, pilot trial. Patients experiencing four to 14 days with migraine during a one-month baseline period were randomized to the orexin receptor antagonist filorexant 10 mg nightly or placebo for three months. Efficacy was assessed by mean monthly migraine days (headache plus at least one associated migraine… 

Figures and Tables from this paper

Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant
TLDR
These data do not provide evidence for the efficacy of nightly filorexant for the treatment of PDN.
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
TLDR
AMG 301 offered no benefit over placebo for migraine prevention; further studies may be necessary to fully understand the role of PACAP isoforms and its receptors in migraine pathophysiology.
Targets for migraine treatment: beyond calcitonin gene-related peptide
TLDR
Following positive phase-III clinical trials, lasmiditan is the first ditan to be FDA-approved and PACAP has experimental evidence suggesting a role in migraine pathophysiology, and the presence of PACAP in key migraine structures along with positive provocative tests for both PACAP-38 andPACAP-27 indicate this pathway may still be a pharmacological target.
The therapeutic impact of new migraine discoveries.
TLDR
Clinical and preclinical studies are needed to untangle the pathophysiology of migraine in order to develop new and migraine-specific therapies, and current therapeutic approaches are not suitable for all migraine patients.
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
TLDR
From a structural perspective, this perspective will focus on the discovery and development of structurally diverse orexin antagonists suitable for preclinical pharmacology studies and human clinical trials.
Emerging drugs for the prevention of migraine
TLDR
The targets discussed in this paper are all on equal footing with each other in terms of their potential as effective novel migraine therapies and there is a need for more clinical trials to pinpoint which of these potential drug targets will be effective for migraine prevention.
Orexin Receptor Gene Polymorphisms in Japanese Migraine Patients with Medication Overuse Headache
TLDR
The results of this study showed that the orexin-related gene polymorphisms are not identified as the contributing factors to the aggravation of migraines due to the overuse of medications.
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
TLDR
The role of orexin receptor antagonists in disorders of sleep/wake and other potential neuropsychiatric conditions, with a focus on suvorexant, which is currently the only approved agent in this class, is outlined.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
TLDR
This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per month compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels.
Topiramate for migraine prevention: a randomized controlled trial.
TLDR
Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase.
Topiramate 100 mg/day in migraine prevention: a pooled analysis of double‐blind randomised controlled trials
TLDR
Topiramate was superior to placebo as measured by the reduction in mean monthly migraine frequency, monthly migraine days and monthly migraine duration and the therapeutic effect was consistent throughout the different studies and independent of gender.
Orexin receptor antagonism for treatment of insomnia
TLDR
The data suggest that orexin receptor antagonism offers a novel approach to treating insomnia, and Class I evidence that suvorexant improves sleep efficiency over 4 weeks in nonelderly adult patients with primary insomnia.
Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
TLDR
Almorexant consistently and dose‐dependently improved sleep variables and may offer a new treatment approach for primary insomnia.
Orexin Receptor Antagonism, a New Sleep‐Promoting Paradigm: An Ascending Single‐Dose Study With Almorexant
TLDR
Vigilance, alertness, and visuomotor and motor coordination were reduced following daytime administration of zolpidem or almorexant at doses of ≥400’mg, and population pharmacokinetic/pharmacodynamic modeling suggested that doses of _500 mg almoreXant and 10  mg zolPidem are equivalent with respect to subjectively assessed alertness.
Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
TLDR
In healthy young men without sleep disorders, suvorexant promoted sleep with some evidence of residual effects at the highest doses, and was well tolerated.
...
1
2
3
4
...